Health
Affinity’s COVID-19 antibodies ready for manufacture for clinical trials – BSA bureau
The study offers a roadmap for speeding development of Monoclonal Antibodies for other diseases; Techniques applied to COVID-19 studies completed Phase 1 Trial
The study offers a roadmap for speeding development of Monoclonal Antibodies for other diseases; Techniques applied to COVID-19 studies completed Phase 1 Trial
Tychan, a Singapore-based clinical-stage biotechnology company focused on developing life-saving treatments through disruptive technologies, announced on 30 July 2020 a publication in New England Journal of Medicine (NEJM) demonstrating the safety and efficacy for TY014, a novel monoclonal antibody candidate treatment for yellow fever (Y…
-
Noosa News14 hours agoReubhan Ralph identified as man behind terrifying childcare centre incident in Peregian Springs on the Sunshine Coast
-
General13 hours agoPolice say new leads being pursued after baby’s body found in Alexander Heights stormwater drain
-
General20 hours agoQueensland announced as 2027 Women’s Softball World Cup host in first Australian event since 1965
-
Noosa News22 hours agoInquest into Rosemarie Campbell’s death three days after gastric bypass surgery hears of ‘massive loss’ to family